ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.18
-0.35 (-2.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close13.53
Open13.75
Bid13.20 x 900
Ask13.45 x 1100
Day's Range13.05 - 14.40
52 Week Range2.75 - 16.47
Volume1,688,392
Avg. Volume2,430,687
Market Cap277.769M
Beta (3Y Monthly)5.92
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.08
  • Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?
    Zacks2 days ago

    Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year?

    Is (ZYNE) Outperforming Other Medical Stocks This Year?

  • UC Davis researcher looks to cannabis compound to treat developmental disorders
    American City Business Journals2 days ago

    UC Davis researcher looks to cannabis compound to treat developmental disorders

    Dr. Randi Hagerman is on the front lines of developing new treatments for kids with autism, Down syndrome and other developmental disorders.

  • Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock
    Zacks3 days ago

    Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue?
    Zacks5 days ago

    Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals, Inc. (ZYNE).

  • Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register?
    Simply Wall St.16 days ago

    Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Associated Press18 days ago

    Zynerba: 1Q Earnings Snapshot

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 47 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire18 days ago

    Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

    DEVON, Pa., May 08, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.

  • Why Zynerba Pharmaceuticals Stock Zoomed Higher Today
    Motley Fool19 days ago

    Why Zynerba Pharmaceuticals Stock Zoomed Higher Today

    The biotech received welcome news from the FDA for lead CBD candidate Zygel.

  • Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy
    American City Business Journals20 days ago

    Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy

    Th FDA awarded the fast track designation to a product the Main Line company is developing to treat patients with Fragile X Syndrome.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia20 days ago

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • GlobeNewswire20 days ago

    Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s lead development candidate Zygel™ (ZYN002 CBD gel) for treatment of behavioral symptoms associated with Fragile X Syndrome (FXS). FDA’s Fast Track program is designed to facilitate the development of drugs intended to treat serious conditions and fill unmet medical needs, and can lead to expedited review by FDA in order to get new important drugs to the patient earlier.

  • Why Zynerba Pharmaceuticals Stock Is Jumping Today
    Motley Fool26 days ago

    Why Zynerba Pharmaceuticals Stock Is Jumping Today

    An analyst's optimistic outlook provided a spark for the small biotech.

  • What's in the Cards for Zynerba (ZYNE) This Earnings Season?
    Zacks26 days ago

    What's in the Cards for Zynerba (ZYNE) This Earnings Season?

    Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

  • Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know
    Zackslast month

    Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know

    In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $10.01, marking a +1.11% move from the previous day.

  • Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?
    Zackslast month

    Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

    Is (ZYNE) Outperforming Other Medical Stocks This Year?

  • Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know
    Zackslast month

    Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $8.23, marking a -0.84% move from the previous day.

  • 5 Marijuana Stocks Wall Street Is Most Bullish On
    Kiplingerlast month

    5 Marijuana Stocks Wall Street Is Most Bullish On

    Cannabis and marijuana stocks are an exciting industry right now. According to Cowen & Co.'s Vivien Azer - a pioneer in cannabis-stock analysis - U.S. marijuana sales are set to reach about $80 billion by 2030. Currently, U.S. legal and illicit sales combined total at least $50 billion. That's on top of an estimated $C12 billion in Canadian revenue by 2025 for both recreational and medical use.The problem? It's still early days for the sector, which means significant risk is involved. It's common to see these primarily small- and mid-cap stocks move 10% or more in response to headlines or quarterly earnings reports. Companies are rushing to establish an early leadership position, and not all of them will end up winners. Plus, the federal legalization of cannabis in the U.S. remains a big question mark.So how do you pinpoint the most compelling investing opportunities in this lucrative industry? One option is to focus on the cannabis stocks that the Street is most bullish on right now.We used TipRanks market data to pinpoint five cannabis and marijuana stocks to buy based on overwhelmingly positive consensus ratings among Wall Street analysts. Let's take a closer look at each. SEE ALSO: Goldman Sachs: 7 Growth Stocks to Buy With Explosive Potential

  • Will Zynerba Pharmaceuticals Continue to Surge Higher?
    Zackslast month

    Will Zynerba Pharmaceuticals Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Zynerba Pharmaceuticals.

  • ACCESSWIRElast month

    These Four Marijuana Stocks Could Make Moves On Thursday

    CORAL GABLES, FL / ACCESSWIRE / April 11, 2019 / Over the course of the last few years, the marijuana stock market has exploded with excitement after years of societal condemnation since the prohibitionary ...

  • Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

    Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

  • Ladenburg Bullish on Zynerba (ZYNE) Stock as ‘FDA Clarifies Its Views on Availability of Non-Prescription CBD’
    SmarterAnalyst2 months ago

    Ladenburg Bullish on Zynerba (ZYNE) Stock as ‘FDA Clarifies Its Views on Availability of Non-Prescription CBD’

    The FDA has started looking into how it might legalize CBD-laced food products, and this is good news for Zynerba (ZYNE) investors.Today, the agency announced it will hold its first public hearings on CBD, as it weighs rules allowing companies to add the popular cannabis-based compound to food. The hearing will be taking place on May 31. In reaction, Zynerba stock skyrocketed nearly 20% in Tuesday's trading session.Ladenburg analyst Michael Higgins believes "the FDA will be taking further steps in 2019 to remove any non-prescription products being sold that include THC and CBD, while allowing the “…production and marketing of hemp, defined as the plant Cannabis sativa L." This would support the market adoption of Zynerba’s Zygel, a CBD gel treatment for children and adolescents with Fragile X syndrome, the most common form of inherited learning disability and attention deficit disorder.As a result, Higgin reiterates a Buy rating on ZYNE stock, along with a price target of $26, which represents a potential upside of 315% from where the stock is currently trading. (To watch Higgin's track record, click here)Higgin commented, "We believe the removal of current CBD-containing foods, lotions, snacks, oils and other embodiments containing CBD favors the market adoption of Zynerba’s Zygel (CBD gel via a sachet). We have long expected the availability of OTC CBD products during Zygel’s marketing (assuming positive pivotal data in Fragile X patients in 2H’19 and approval in 2H’20), but the stance of the agency suggests less availability of CBD-containing products for which consumers to choose from. From our research, today’s CBDinfused products deliver substantially lower levels of CBD with some containing other active ingredients from the marijuana plant, including THC. We believe this morning's publication reflects the agency’s loss of patience with these products as the number of and marketing of these products have become more ubiquitous and aggressive. While 33 states allow “medical” marijuana the FDA lists marijuana as, “…Schedule I of the CSA (Controlled Substances Act) due to its high potential for abuse, which is attributable in large part to the psychoactive effects of THC, and the absence of a currently accepted medical use for marijuana in the United States” (today’s Fed Reg). In our view, the agency is not relenting, rather, it is leaning on the regulatory statutes several times in this morning's publication."All in all, the legalization of hemp and hemp-based CBD is expected create substantial opportunities for a handful of publicly traded companies, such as Zynerba. Overall, this cannabis stock stands as a 'Strong Buy' name among Wall Street analysts. In the last three months, ZYNE has won 3 bullish 'buy' ratings, with no 'hold' or 'sell' ratings. With a return potential of nearly 220%, the stock's consensus target price stands at $20.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * General Electric (GE) Stock at $14-16 a Share? This Analyst Thinks It’s Possible * Lyft (LYFT) Stock Looks Like It Can Rally Back to $78, Says Analyst * CannTrust (CTST): One Bad Sign for This Cannabis Stock * Lyft (LYFT) Stock Looks Like It Can Rally Back to $78, Says Analyst

  • GlobeNewswire2 months ago

    Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

    Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2019 H.C. Wainwright Global Life Sciences Conference. The presentation will take place on Tuesday, April 9, 2019 at 12:10 PM BST at the Grosvenor House in London, UK. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.

  • ACCESSWIRE2 months ago

    Cannabis Breakout Candidates - THC Therapeutics, Inc. (THCT)

    HENDERSON, NV / ACCESSWIRE / March 22, 2019 / Many high-profile companies in the cannabis market have posted incredible gains since start of 2019 and this trend looks to continue. The race to profit from ...